中药消水方对小鼠肺癌转移瘤胸腔积液的抑制作用
|
摘要
目的:观察中药消水方对小鼠肺癌转移瘤胸腔积液的抑制作用。方法:采用荧光标记的Lewis肺癌细胞胸腔注射建立C57BL/6小鼠肺癌转移瘤胸腔积液模型,建模第3天后,随机分为消水方组(XSF组)、顺铂组(DDP组)、消水方+顺铂组(XSF+DDP组)、模型组(Control组),每组10只,给药10d,第14天时各组取10只小鼠处死取材,收集胸水并测量胸水体积、胸壁转移瘤个数以及转移瘤重。给药期间,分别于第3、8、13天时采用小动物活体成像系统观察转移瘤胸腔积液生长情况。结果:第8天时XSF+DDP组、DDP组的荧光强度值分别与Control组比较有显著差异(P<0.05);第13天时XSF+DDP组荧光强度值与DDP组、XSF组、Control组比较,均有显著差异(P<0.05)。XSF+DDP组胸腔积液体积最小,为(177±64)μL,与XSF组、DDP组比较,差异均具有统计学意义(P<0.05)。XSF+DDP组转移瘤个数也为最少,为(2.5±1.0)个。与XSF组比较,XSF+DDP组与DDP组胸壁转移瘤个数显著减少(P<0.05)。DDP组转移瘤重最轻,为(111.0±43.9)mg。与XSF组比较,XSF+DDP组、DDP组瘤重均显著降低(P<0.01);并且XSF+DDP、DDP两组比较,亦有显著差异(P<0.05)。结论:中药消水方对于小鼠肺癌转移瘤胸腔积液具有一定抑制作用,且联合顺铂后作用更加显著。
Objective: To observe the inhibitory effect of Xiaoshui Formula on pleural effusion of lung cancer metastatic tumors in model mice. Methods: The pleural effusion model of C57 BL/6 mice with lung cancer metastases were established by injecting fluorescent labeled Lewis lung cancer cells into thoracic cavity. After the third day of modeling, all mouse were randomly divided into four groups: Xiaoshui Formula group(XSF group), cisplatin group(DDP group), Xiaoshui Formula and cisplatin group(XSF+DDP group) and control group, 10 mice in each group, and administration for 10 days. On the 14 th day, each group of 10 mice were sacrificed to collect pleural effusion, and the volume of pleural effusion, the number of metastatic tumors in the chest wall and the weight of metastatic tumors were measured. During the administration period, the growth of pleural effusion in metastatic tumors was observed by small animal imaging system on the 3 rd, 8 th and 13 th day respectively. Results: On the 8 th day, the fluorescence intensity of XSF+DDP group and DDP group was different from that of control group(P<0.05); on the 13 th day, XSF+DDP group was significantly different from that in DDP group, XSF group and control group(P<0.05). The volume of pleural effusion in XSF+DDP group was the smallest [(177±64) μL], which was statistically significant compared with XSF group and DDP group(P<0.05). The number of metastatic tumors in XSF+DDP group was also the least(2.5±1.0). Compared with XSF group, the number of metastatic tumors in DDP group was decreased(P<0.05). The weight of metastatic tumors in DDP group was the lightest(111.0±43.9) mg. Compared with XSF group, the weight of metastatic tumors in XSF+DDP group and DDP group was decreased(P<0.01), and there were significant differences between XSF+DDP group and DDP group(P<0.05).Conclusion: The traditional Chinese medicine Xiaoshui Formula has a certain inhibitory effect on pleural effusion of lung cancer metastatic tumors in model mice, and the effect is more significant after combined with cisplatin.
Objective: To observe the inhibitory effect of Xiaoshui Formula on pleural effusion of lung cancer metastatic tumors in model mice. Methods: The pleural effusion model of C57 BL/6 mice with lung cancer metastases were established by injecting fluorescent labeled Lewis lung cancer cells into thoracic cavity. After the third day of modeling, all mouse were randomly divided into four groups: Xiaoshui Formula group(XSF group), cisplatin group(DDP group), Xiaoshui Formula and cisplatin group(XSF+DDP group) and control group, 10 mice in each group, and administration for 10 days. On the 14 th day, each group of 10 mice were sacrificed to collect pleural effusion, and the volume of pleural effusion, the number of metastatic tumors in the chest wall and the weight of metastatic tumors were measured. During the administration period, the growth of pleural effusion in metastatic tumors was observed by small animal imaging system on the 3 rd, 8 th and 13 th day respectively. Results: On the 8 th day, the fluorescence intensity of XSF+DDP group and DDP group was different from that of control group(P<0.05); on the 13 th day, XSF+DDP group was significantly different from that in DDP group, XSF group and control group(P<0.05). The volume of pleural effusion in XSF+DDP group was the smallest [(177±64) μL], which was statistically significant compared with XSF group and DDP group(P<0.05). The number of metastatic tumors in XSF+DDP group was also the least(2.5±1.0). Compared with XSF group, the number of metastatic tumors in DDP group was decreased(P<0.05). The weight of metastatic tumors in DDP group was the lightest(111.0±43.9) mg. Compared with XSF group, the weight of metastatic tumors in XSF+DDP group and DDP group was decreased(P<0.01), and there were significant differences between XSF+DDP group and DDP group(P<0.05).Conclusion: The traditional Chinese medicine Xiaoshui Formula has a certain inhibitory effect on pleural effusion of lung cancer metastatic tumors in model mice, and the effect is more significant after combined with cisplatin.
引文
[1]Lombardi G,Zustovich F,Nicoletto M O,et al.Diagnosis andtreatment of malignant pleural effusion:a systematic literaturereview and new approaches.Am J Clin Oncol,2010,33(4):420
[2]AntunesG,NevilleE,DuffyJ,etal.BTSguidelinesforthe management of malignant pleural effusions.Thorax,2003,58(S2):29-38
[3]施展,路晓光,刘睿,等.消水方联合顺铂治疗恶性胸腔积液的临床观察.中华中医药杂志,2012,27(4):1164-1166
[4]Shi Z,He Q,Hua B.Clinical observation on the efficacy of Xiaoshuidecoction(消水方)combined with intrapleural perfusion ofcisplatin in treating malignant pleural effusion.Chinese Journal ofIntegrative Medicine,2008,14(4):257-261
[5]Stathopoulos G T,Zhu Z,Everhart M B,et al.Nuclear factor-κBaffects tumor progression in a mouse model of malignant pleuraleffusion.American Journal of Respiratory Cell and MolecularBiology,2006,34(2):142
[6]Stathopoulos G T,Kalomenidis I.Animal models of malignantpleural effusion.Curr Opin Pulm Med,2009,15(4):343-52
[7]Agalioti T,Giannou A D,Krontira A C,et al.Mutant KRAS promotesmalignant pleural effusion formation.Nat Commun,2017,8:15205
[8]金志超,施展,花宝金.中药口服汤剂联合顺铂胸腔灌注治疗肺癌恶性胸腔积液临床疗效的Meta分析.中华中医药杂志,2018,33(5):478-482
[9]蔡江南,刘海涛,毕东敏,等.葶苈大枣泻肺汤加味联合顺铂治疗肺癌恶性胸腔积液21例临床观察.湖南中医杂志,2017,33(2):46-48
[10]Drake J M,Gabriel C L,Henry M D.Assessing tumor growthand distribution in a model of prostate cancer metastasis usingbioluminescence imaging.Clinical and Experimental Metastasis,2005,22(8):674-684
[11]Stathopoulos G T,Moschos C,Loutrari H,et al.Zoledronic acidis effective against experimental malignant pleural effusion.American Journal of Respiratory and Critical Care Medicine,2008,178(1):50-59
[12]Psallidas I,Karabela S P,Moschos C,et al.Specific effects ofbortezomib against experimental malignant pleural effusion:A preclinical study.Molecular Cancer,2010,9(1):1-11
[13]Moschos C,Psallidas I,Cottin T,et al.A sulindac analogue iseffective against malignant pleural effusion in mice.Lung Cancer,2011,73(2):171-175
[14]Fang F,Chen P,Wu X,et al.Therapeutic effects of recombinanthuman endostatin adenovirus in a mouse model of malignantpleural effusion.Journal of Cancer Research and Clinical Oncology,2009,135(9):1149-1157
[2]AntunesG,NevilleE,DuffyJ,etal.BTSguidelinesforthe management of malignant pleural effusions.Thorax,2003,58(S2):29-38
[3]施展,路晓光,刘睿,等.消水方联合顺铂治疗恶性胸腔积液的临床观察.中华中医药杂志,2012,27(4):1164-1166
[4]Shi Z,He Q,Hua B.Clinical observation on the efficacy of Xiaoshuidecoction(消水方)combined with intrapleural perfusion ofcisplatin in treating malignant pleural effusion.Chinese Journal ofIntegrative Medicine,2008,14(4):257-261
[5]Stathopoulos G T,Zhu Z,Everhart M B,et al.Nuclear factor-κBaffects tumor progression in a mouse model of malignant pleuraleffusion.American Journal of Respiratory Cell and MolecularBiology,2006,34(2):142
[6]Stathopoulos G T,Kalomenidis I.Animal models of malignantpleural effusion.Curr Opin Pulm Med,2009,15(4):343-52
[7]Agalioti T,Giannou A D,Krontira A C,et al.Mutant KRAS promotesmalignant pleural effusion formation.Nat Commun,2017,8:15205
[8]金志超,施展,花宝金.中药口服汤剂联合顺铂胸腔灌注治疗肺癌恶性胸腔积液临床疗效的Meta分析.中华中医药杂志,2018,33(5):478-482
[9]蔡江南,刘海涛,毕东敏,等.葶苈大枣泻肺汤加味联合顺铂治疗肺癌恶性胸腔积液21例临床观察.湖南中医杂志,2017,33(2):46-48
[10]Drake J M,Gabriel C L,Henry M D.Assessing tumor growthand distribution in a model of prostate cancer metastasis usingbioluminescence imaging.Clinical and Experimental Metastasis,2005,22(8):674-684
[11]Stathopoulos G T,Moschos C,Loutrari H,et al.Zoledronic acidis effective against experimental malignant pleural effusion.American Journal of Respiratory and Critical Care Medicine,2008,178(1):50-59
[12]Psallidas I,Karabela S P,Moschos C,et al.Specific effects ofbortezomib against experimental malignant pleural effusion:A preclinical study.Molecular Cancer,2010,9(1):1-11
[13]Moschos C,Psallidas I,Cottin T,et al.A sulindac analogue iseffective against malignant pleural effusion in mice.Lung Cancer,2011,73(2):171-175
[14]Fang F,Chen P,Wu X,et al.Therapeutic effects of recombinanthuman endostatin adenovirus in a mouse model of malignantpleural effusion.Journal of Cancer Research and Clinical Oncology,2009,135(9):1149-1157